The collaboration between Biomea Fusion and the Leicester Diabetes Centre introduces a new experimental arm within the adaptive OPAL platform trial to evaluate the combination of icovamenib and semaglutide. This clinical investigation will examine whether a short course of the investigational menin inhibitor can amplify the benefits of a GLP-1 receptor agonist while protecting muscle and bone, not just reducing body weight.
The randomized, double-blind comparison will enroll adults without type 2 diabetes who are either overweight with at least one weight-related complication or obese. Participants will receive either icovamenib added to low-dose semaglutide or low-dose semaglutide alone, with the primary evaluation scheduled at Week 24. Enrollment is planned to commence in the third quarter.
Rationale and scientific background
Recent preclinical work informed this clinical move. In animal models, the addition of icovamenib to low-dose semaglutide produced greater fat loss and improved glycemic markers while helping to maintain lean mass. Those results suggested complementary biological actions: semaglutide reduces appetite and energy intake through central and peripheral mechanisms, while icovamenib appears to act on pathways linked to beta cell biology and tissue metabolism.
Biomea’s investigations into menin inhibition show that targeting this transcriptional regulator can modify cellular programs related to pancreatic islets and metabolic tissues. Preclinical ex vivo studies and rodent models pointed to enhanced weight reduction driven by fat loss with preserved muscle, providing the scientific basis for testing the combination in humans.
Design of the OPAL arm and endpoints
The new arm will test a 12-week course of icovamenib at 100 mg once daily together with 24 weeks of low-dose semaglutide, compared with 24 weeks of low-dose semaglutide alone. This randomized, double-blinded format will evaluate the combination in participants without established diabetes, focusing on outcomes that move beyond simple weight metrics.
Primary and secondary measures
The primary outcome is assessed at Week 24 and emphasizes comprehensive functional and compositional endpoints rather than body weight alone. Key secondary measures include changes in body composition (fat and muscle mass), walking performance as a proxy for physical function, bone-related parameters, glycemic control markers, and patient-reported quality of life. The OPAL platform also allows future comparisons with structured exercise interventions and diet-induced weight loss arms.
Why physical function matters
Investigators underscore that clinically meaningful benefit requires preserving or improving functional capacity. As Professor Melanie Davies CBE explains, the goal is to protect muscle and mobility while reducing adiposity. Professor Thomas Yates adds that emerging weight loss medicines need assessment for impacts on skeletal integrity and functional outcomes, not just body weight.
Collaboration dynamics and scientific dissemination
Biomea Fusion and the University of Leicester bring complementary strengths: industry-driven drug development experience paired with the academic center’s broad translational research infrastructure. Thorsten Kirschberg, PhD, EVP of Research at Biomea, emphasized that the preclinical synergy observed between icovamenib and semaglutide motivated the clinical evaluation and that partnering with one of Europe’s leading metabolic research centers enables rigorous assessment.
In parallel, Biomea will present late-breaking preclinical data at the 86th American Diabetes Association Scientific Sessions. The poster, titled Menin inhibitor icovamenib activates mechanisms that support metabolic health (poster #2871-LB), is scheduled for June 7, 2026 from 12:30 to 1:30 pm CT. Those findings aim to clarify mechanistic pathways through which menin inhibition may bolster metabolic outcomes.
Implications for treatment strategies
If the OPAL arm confirms the preclinical signals, the combination could offer a strategy to enhance weight loss achieved with GLP-1 therapies while lessening undesirable lean tissue loss. For patients and clinicians, that could translate into more durable improvements in mobility, metabolic control, and overall quality of life. The trial’s detailed assessments of muscle, bone, and metabolic biomarkers are designed to provide the data needed to evaluate that hypothesis.
Beyond the immediate study, Biomea’s development program for icovamenib continues in Phase 2 for diabetes indications, and the company is advancing additional oral small molecules for metabolic disease. The OPAL collaboration illustrates an expanding approach in obesity and diabetes research: combine complementary pharmacology with functional endpoints to define therapies that deliver broad, clinically meaningful benefits.
